PO:09:247 Anifrolumab in systemic lupus erythematosus with renal involvement: national multicenter registry in clinical practice

Abstracts%), class II+V (n= 1; 1.5 %) and class III+V (n= 1; 1.5 %).The main extrarenal and renal manifestations are shown in the table 1.The treatments previously received were (n): steroids (67), cyclophosphamide (CYM) (25), rituximab (RTX) (9), mycophenolate mofetil (MMF) (56), azathioprine (AZA) (11), antimalarials (62), tacrolimus (8) and belimumab (BLM) (12).After a meanSD duration of treatment until non-response of 16.19.5months, worsening of renal failure (25%), persistent proteinuria (61.76%) and persistent proteinuria and renal failure (13.24%).The evolution of creatinine, proteinuria in 24-hour urine, C3 and C4 levels are shown in the figure 1.The treatment received after non-response was: steroids (n= 50), CYM ( 16), RTX (n= 19), MMF (n= 41), AZA (n= 11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) ( 19) and anifrolumab (1).After a follow-up of 59.746 months, 41 patients (60.3%) achieved remission.However, 6 patients need hemodialysis and 4 a kidney transplant.The main complications of these 68 patients were: infections (n= 21), cervical intraepithelial neoplasia (n=1) avascular necrosis of the hip (n= 2), pulmonary thromboembolism (n= 1), comminuted ankle and radial head fracture (n= 1) and oligomenorrhea (n= 1).Conclusions More than half of patients achieve remission after modifying or intensifying initial immunosuppressive therapy.